FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564622493> ?p ?o ?g. }

• W2564622493 endingPage "6969" @default.
• W2564622493 startingPage "6955" @default.
• W2564622493 abstract "// Ilaria Grossi 1 , Bruna Arici 1 , Nazario Portolani 2 , Giuseppina De Petro 1 , Alessandro Salvi 1 1 Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, Brescia, Italy 2 Department of Clinic and Experimental Sciences, Surgical Clinic, University of Brescia, Brescia, Italy Correspondence to: Alessandro Salvi, email: alessandro.salvi@unibs.it Giuseppina De Petro, email: giuseppina.depetro@unibs.it Keywords: microRNAs, epigenetics, 5-Aza-2’-deoxycytidine, HCC, molecular targets Received: April 11, 2016     Accepted: December 16, 2016     Published: December 28, 2016 ABSTRACT Hepatocellular carcinoma (HCC) is the most common cancer of the liver with a very poor prognosis. The dysregulation of microRNAs (miRs) is indeed implicated in HCC onset and progression. In this study, we have evaluated the expression of miR-23b and miR-193a in a large cohort of 59 and 67 HCC patients, respectively. miR-23b and miR-193a resulted significantly down-regulated in primary HCCs compared to their matched peritumoral counterparts. Furthermore, patients with higher miR-193a expression exhibited longer OS and DFS, suggesting that miR-193a may be a molecular prognostic factor for HCC patients. Since the regulation of miRs by DNA methylation may occur in human cancers, we verified whether the down-modulation of miR-23b and miR-193a in HCC tissues could be related to DNA methylation. An inverse trend between miR-23b expression and DNA methylation was observed, indicating that miR-23b can be epigenetically regulated. By contrast, the down-regulation of miR-193a was not mediated by DNA methylation. To verify the potential role of miR-23b and miR-193a as responsive molecular targets in vitro , we used the inhibitor of DNA methylation 5-aza-dC to restore miR-23b expression level in combination with miR-193a transfection. The combined treatment led to a significant inhibition of cellular proliferation and migration. Taken together, our findings provide evidence that miR-23b and miR-193a may be molecular diagnostic and prognostic factors for HCC; furthermore, miR-23b and miR-193a are responsive molecular targets for limiting HCC cell aggressiveness in combination with the epigenetic drug 5-aza-dC. Moreover, our results provide new advances in the epigenetic regulation of these miRs in HCC." @default.
• W2564622493 created "2017-01-06" @default.
• W2564622493 creator A5012461540 @default.
• W2564622493 creator A5057939408 @default.
• W2564622493 creator A5060414606 @default.
• W2564622493 creator A5072021164 @default.
• W2564622493 creator A5083743682 @default.
• W2564622493 date "2016-12-28" @default.
• W2564622493 modified "2023-10-18" @default.
• W2564622493 title "Clinical and biological significance of miR-23b and miR-193a in human hepatocellular carcinoma" @default.
• W2564622493 cites W1514970182 @default.
• W2564622493 cites W1565938690 @default.
• W2564622493 cites W1566057190 @default.
• W2564622493 cites W1825553076 @default.
• W2564622493 cites W1855442143 @default.
• W2564622493 cites W1879966002 @default.
• W2564622493 cites W1883333379 @default.
• W2564622493 cites W1905483344 @default.
• W2564622493 cites W1966749076 @default.
• W2564622493 cites W1971837077 @default.
• W2564622493 cites W1975533496 @default.
• W2564622493 cites W1985068428 @default.
• W2564622493 cites W1990869991 @default.
• W2564622493 cites W1994193851 @default.
• W2564622493 cites W2000940387 @default.
• W2564622493 cites W2005139620 @default.
• W2564622493 cites W2013304110 @default.
• W2564622493 cites W2036982851 @default.
• W2564622493 cites W2046100841 @default.
• W2564622493 cites W2046959378 @default.
• W2564622493 cites W2052687565 @default.
• W2564622493 cites W2057846741 @default.
• W2564622493 cites W2070031183 @default.
• W2564622493 cites W2081871084 @default.
• W2564622493 cites W2082399298 @default.
• W2564622493 cites W2087846605 @default.
• W2564622493 cites W2089801128 @default.
• W2564622493 cites W2093468083 @default.
• W2564622493 cites W2096460033 @default.
• W2564622493 cites W2096567469 @default.
• W2564622493 cites W2103689264 @default.
• W2564622493 cites W2117991443 @default.
• W2564622493 cites W2135733051 @default.
• W2564622493 cites W2136783734 @default.
• W2564622493 cites W2137031237 @default.
• W2564622493 cites W2139056019 @default.
• W2564622493 cites W2148812348 @default.
• W2564622493 cites W2158378236 @default.
• W2564622493 cites W2160017949 @default.
• W2564622493 cites W2171420082 @default.
• W2564622493 cites W2188190150 @default.
• W2564622493 cites W2196397027 @default.
• W2564622493 cites W2302342224 @default.
• W2564622493 doi "https://doi.org/10.18632/oncotarget.14332" @default.
• W2564622493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5351682" @default.
• W2564622493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28036298" @default.
• W2564622493 hasPublicationYear "2016" @default.
• W2564622493 type Work @default.
• W2564622493 sameAs 2564622493 @default.
• W2564622493 citedByCount "24" @default.
• W2564622493 countsByYear W25646224932017 @default.
• W2564622493 countsByYear W25646224932018 @default.
• W2564622493 countsByYear W25646224932019 @default.
• W2564622493 countsByYear W25646224932020 @default.
• W2564622493 countsByYear W25646224932021 @default.
• W2564622493 countsByYear W25646224932022 @default.
• W2564622493 countsByYear W25646224932023 @default.
• W2564622493 crossrefType "journal-article" @default.
• W2564622493 hasAuthorship W2564622493A5012461540 @default.
• W2564622493 hasAuthorship W2564622493A5057939408 @default.
• W2564622493 hasAuthorship W2564622493A5060414606 @default.
• W2564622493 hasAuthorship W2564622493A5072021164 @default.
• W2564622493 hasAuthorship W2564622493A5083743682 @default.
• W2564622493 hasBestOaLocation W25646224931 @default.
• W2564622493 hasConcept C104317684 @default.
• W2564622493 hasConcept C126322002 @default.
• W2564622493 hasConcept C143998085 @default.
• W2564622493 hasConcept C145059251 @default.
• W2564622493 hasConcept C150194340 @default.
• W2564622493 hasConcept C190727270 @default.
• W2564622493 hasConcept C2778019345 @default.
• W2564622493 hasConcept C2779314089 @default.
• W2564622493 hasConcept C33288867 @default.
• W2564622493 hasConcept C41091548 @default.
• W2564622493 hasConcept C502942594 @default.
• W2564622493 hasConcept C54355233 @default.
• W2564622493 hasConcept C71924100 @default.
• W2564622493 hasConcept C86803240 @default.
• W2564622493 hasConceptScore W2564622493C104317684 @default.
• W2564622493 hasConceptScore W2564622493C126322002 @default.
• W2564622493 hasConceptScore W2564622493C143998085 @default.
• W2564622493 hasConceptScore W2564622493C145059251 @default.
• W2564622493 hasConceptScore W2564622493C150194340 @default.
• W2564622493 hasConceptScore W2564622493C190727270 @default.
• W2564622493 hasConceptScore W2564622493C2778019345 @default.
• W2564622493 hasConceptScore W2564622493C2779314089 @default.
• W2564622493 hasConceptScore W2564622493C33288867 @default.
• W2564622493 hasConceptScore W2564622493C41091548 @default.

• next